Confusion Regarding Duration of Insulin Action

People with diabetes on insulin pumps often use a bolus calculator (BC) to obtain insulin dose recommendations. After the first bolus of the day, residual insulin activity, called bolus insulin on board (BOB), must be correctly accounted for to reduce the size of subsequent boluses and minimize the insulin stacking that would otherwise occur. Critical to achieving this calculation is having an appropriate duration of insulin action (DIA) setting in the BC. Unfortunately, the widespread use of inappropriately short DIAs may be causing unrecognized “stacking” of insulin that leads to unexplained hypoglycemic events. Currently, there is no widely accepted definition or value of the DIA for use in a BC. Various shortcomings regarding the selection of an appropriate DIA setting have led to considerable confusion among clinicians and insulin pump users about this important concept. Traditional pharmacological studies used to determine the pharmacodynamic (PD) properties of rapid-acting insulins create a misleading impression that insulin action times (IATs) in daily life vary from 3 to 5 hours and cause IATs to appear more variable than they actually are. These IAT time ranges are not appropriate for use as the DIA time value required to obtain an accurate bolus recommendation from a BC. We highlight the problems that arise when an inappropriately short DIA leads to excessive bolus recommendations, provide a research protocol to accurately measure DIA, and suggest appropriate DIA time recommendations for use in current clinical practice.

[1]  Lutz Heinemann,et al.  Measurement of insulin absorption and insulin action. , 2004, Diabetes technology & therapeutics.

[2]  L. Heinemann,et al.  Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy , 2009, Diabetes Care.

[3]  I. Hirsch,et al.  Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.

[4]  S. Mudaliar,et al.  Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.

[5]  L. Heinemann,et al.  Dose–response relationship of insulin glulisine in subjects with type 1 diabetes , 2009, Diabetes care.

[6]  L. Heinemann,et al.  Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin , 1998, Diabetes Care.

[7]  T. Bailey,et al.  Guidelines for Optimal Bolus Calculator Settings in Adults , 2011, Journal of diabetes science and technology.

[8]  W. Roberts,et al.  Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. , 2004, Clinical chemistry.

[9]  Eyal Dassau,et al.  Bolus calculator: a review of four "smart" insulin pumps. , 2008, Diabetes technology & therapeutics.

[10]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[11]  L. Heinemann,et al.  Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. , 1998, Diabetes care.

[12]  S. Steiner,et al.  A novel insulin formulation with a more rapid onset of action , 2008, Diabetologia.

[13]  S. Donath,et al.  Poor adherence to integral daily tasks limits the efficacy of CSII in youth , 2011, Pediatric diabetes.

[14]  J. Tauber,et al.  Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. , 2000, Diabetes care.

[15]  L. Heinemann,et al.  Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.

[16]  Subcutaneous Injection versus Subcutaneous Infusion of Insulin: Are the Rates of Absorption Truly the Same? , 2011, Journal of diabetes science and technology.

[17]  B. Olsen,et al.  Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes , 2000, European Journal of Pediatrics.

[18]  Lutz Heinemann,et al.  Variability of insulin absorption and insulin action. , 2002, Diabetes technology & therapeutics.

[19]  B. Sugarman,et al.  Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. , 2009, Diabetes technology & therapeutics.

[20]  K. Minaker,et al.  Escape of hepatic glucose production during hyperglycemic clamp. , 1989, The American journal of physiology.

[21]  John Walsh,et al.  Guidelines for Insulin Dosing in Continuous Subcutaneous Insulin Infusion Using New Formulas from a Retrospective Study of Individuals with Optimal Glucose Levels , 2010, Journal of diabetes science and technology.

[22]  L. Heinemann,et al.  Ultrafast-Acting Insulins: State of the Art , 2012, Journal of diabetes science and technology.

[23]  L. Heinemann,et al.  Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.